Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
NCT01392378 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 908
Last updated 2014-02-26
Summary
The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination. Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination.
Conditions
- Pneumococcal Vaccines
Interventions
- BIOLOGICAL
-
13-valent pneumococcal conjugate vaccine
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- BIOLOGICAL
-
INFANRIX hexa
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- DRUG
-
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
- BIOLOGICAL
-
13-valent pneumococcal conjugate vaccine
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- BIOLOGICAL
-
INFANRIX hexa
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- DRUG
-
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
- BIOLOGICAL
-
13-valent pneumococcal conjugate vaccine
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- BIOLOGICAL
-
INFANRIX hexa
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- DRUG
-
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
- BIOLOGICAL
-
13-valent pneumococcal conjugate vaccine
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- BIOLOGICAL
-
INFANRIX hexa
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- DRUG
-
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
- BIOLOGICAL
-
13-valent pneumococcal conjugate vaccine
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
- BIOLOGICAL
-
INFANRIX hexa
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 56 Days
- Max Age
- 98 Days
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-08-31
- Primary Completion
- 2013-01-31
- Completion
- 2013-01-31
Countries
- Poland
Study Locations
More Related Trials
-
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
NCT00452790 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366678 ·Status: COMPLETED ·Phase: PHASE3
-
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
NCT05408429 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
NCT00370396 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
NCT01193335 ·Status: COMPLETED ·Phase: PHASE4
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00344318 ·Status: COMPLETED ·Phase: PHASE3
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
NCT01545375 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
NCT00444457 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
NCT00824655 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
NCT06622109 ·Status: ACTIVE_NOT_RECRUITING
-
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
NCT00907777 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
NCT03574389 ·Status: COMPLETED ·Phase: PHASE3
-
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
NCT00489554 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
NCT00390910 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
NCT01026038 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Prevnar 13 on Ear Infections in Children
NCT01272999 ·Status: COMPLETED
-
A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
NCT01692886 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT02494999 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00384059 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety Study For Prevenar 13 Among Chinese Children
NCT03656939 ·Status: COMPLETED
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00368966 ·Status: COMPLETED ·Phase: PHASE3